Erlotinib, a kind of TKI, can inhibit tumor development by inhibiting intracellular phosphorylation of EGFR-related tyrosine kinases, which commonly used in the treatment of NSCLC and pancreatic cancer. Here, EGFR is linked to non-small cell lung carcinoma.